Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (October 2019)
27 slides from Pyc Therapeutics's investor presentation, Oct 31, 2019
Slide 1: Entitlement offer – Investor Presentation
Entitlement offer – Investor Presentation October 2019
Slide 2: Important statements and Disclaimer
Important statements and Disclaimer • The purpose of this presentation is to provide general information about Phylogica Limited (“PYC” or the “Company”). This presentation relates to a proposed accelerated pro rata non-renounceable entitlement offer (the “Entitlement Offer”) of new shares in the Co
Slide 3: Entitlement offer structure
Entitlement offer structure ▪ A$26.8M entitlement offer at A$0.055 per share ▪ 1 for 5 fully underwritten accelerated non-renounceable entitlement offer for eligible shareholders ▪ Entitlement Offer is fully underwritten by Australian Land Pty Ltd, an entity controlled by the Company's Non-Executive
Slide 4: Indicative timetable
Indicative timetable Key event Date Announcement of the Entitlement Offer 31 October 2019 Institutional Entitlement Offer Opens 31 October 2019 Institutional Entitlement Offer Closes 1 November 2019 Shares recommence trading on ASX on an “ex-entitlement” basis 4 November 2019 Record Date for eligibi
Slide 5: PYC will use the proceeds of this entitlement offer to bring our lead program to market
PYC will use the proceeds of this entitlement offer to bring our lead program to market and build out our drug development pipeline Time period 2020 2021 Beyond Total Use of funds Lead Program $10m (IND-enabling) $5m Anticipate funded $15m through to market with R&D rebate Programs 2-4 to $5m $5m $1
Slide 6: With our lead program funded through to market, we can look to expand
With our lead program funded through to market, we can look to expand our precision medicine approach across additional diseases Our post entitlement position will enable PYC to deliver on our core strategy to deliver shareholder return Program Discovery Pre-clinical Clinical Marketed Ocular Inherit
Slide 7: PYC Corporate snapshot
PYC Corporate snapshot Financial Information (assumes successful completion of Share price performance (1 year) Entitlement Offer) Share price (AUD) Volume (m) Share price (30/10/2019) $0.062 Number of shares 2,931M Market Capitalisation $182M Pro forma Cash post $33M transaction Debt (1-Nov-19) Nil
Slide 8: The delivery challenge: getting big drugs inside cells
The delivery challenge: getting big drugs inside cells Solving the ‘delivery challenge’ opens the door to new treatments and breakthrough medicines Opportunity Highest value drug targets exist inside cells Challenge But… The cell membrane has evolved over hundreds of millions of years to keep foreig
Slide 9: PYC Therapeutics solves the delivery challenge with our CPP technology
PYC Therapeutics solves the delivery challenge with our Cell- Penetrating Peptide (CPP) technology PYC Therapeutics’ solution PYC’s Cell Penetrating Peptides (CPPs) cross the cell membrane and can be joined to a drug cargo to deliver it inside the cell CPP Drug CPP-Drug complex Precision medicine is
Slide 10: Why does this matter? A human example (1/3) – PYC's lead drug program
Why does this matter? A human example (1/3) – PYC’s lead drug program Key points Normal vision ▪ Retinitis Pigmentosa (RP) is the leading cause of childhood blindness ▪ Children with RP lose their night vision before progressing through peripheral visual loss and ultimately to blindness Vision with
Slide 11: Why does this matter? A human example (2/3)
Why does this matter? A human example (2/3) Cell type: Healthy cells Diseased cells Diseased cells Diseased cells Treatment: None None Drug alone Delivery + Drug Illustration: Image of actual human cells: PYC’s ‘delivery + drug’ solution reverses the disease process and restores the cilia (in red) e
Slide 12: Why does this matter? A human example (3/3)
Why does this matter? A human example (3/3) Milestone Animal models Human cells 3D ‘retina in a Humans Patient impact dish’ models and Revenue PYC’s lead drug Is 4x more Has reversed Has proven to Will prove Will create the first program… effective in our target be highly effective in treatment for
Slide 13: PYC has a clear competitive advantage in the amount of drug cargo that we can deliver
PYC has a clear competitive advantage in the amount of drug cargo that we can deliver PYC’s delivery technology delivers 4x more drug Getting enough drug cargo inside the cell is the rate- cargo inside cells than our nearest competitor’s limiting step in the development of precision drugs % of cells
Slide 14: We drive shareholder returns through two commercial applications of our delivery platform
We drive shareholder returns through two commercial applications of our delivery ‘platform’ 1 Development of PYC’s own pipeline of drugs PYC’s delivery platform ▪ Develop PYC’s own drug cargoes for our + initial area of focus - Genetic Eye Diseases PYC’s drug 2 Licensing PYC’s PYC’s delivery platfor
Slide 15: Our lead program has major de-risking events immediately ahead
Our lead program has major de-risking events immediately ahead with 1 assessment in 3D models of multiple patient retinas in Q1 2020 Lead drug program – Retinitis Pigmentosa Pre- IND- Development stage Discovery Phase 1 Phase 2 Phase 3 Marketing clinical enabling Current progress We are here Timelin
Slide 16: Our technology scales rapidly and is capable of supporting internal programs and out-licensing
2 Our technology scales rapidly and is capable of supporting both internal programs and out-licensing opportunities Developmental stage of PYC and Partner’s pipeline in 2020 Program Discovery Pre-clinical Clinical Marketed Ocular Inherited retinal disease #1 Inherited retinal disease #2 Programs #2
Slide 17: PYC trades substantially below the valuation of our peers
PYC trades substantially below the valuation of our peers Eye disease landscape examples Antisense Oligo landscape examples Geographic base Australia US US Netherlands US Platform or asset Platform Platform Asset Asset Platform Development stage Pre-clinical Clinical (Phase 1) Clinical (Phase 2) Cli
Slide 18: We have a world-class scientific team
We have a world-class scientific team Scientific Advisory Board Opthamology Advisory Board Operational Team Prof. Judy Lieberman Fred K. Chen Rohan Hockings MD, Ph.D MBBS (Hons), Ph.D, FRANZCO MBBS (Hons.), JD GDLP Professor of Pediatrics at Clinician and leader of Ocular Tissue Engineering Laborato
Slide 19: Appendix: General risks
Appendix: General risks Securities investments There are risks associated with any securities investment. The prices at which the securities of the Company trade may fluctuate in response to a number of factors. Furthermore, the stock market, and in particular the market for biotechnology companies,
Slide 20: Appendix: Risks specific to an investment in the Company
Appendix: Risks specific to an investment in the Company Technology risks For the Company to be competitive in the drug discovery and development market, the Directors expect it will need to continue to develop or acquire new technologies and platforms, develop niche markets and to take early advant
Slide 21: Appendix: Risks specific to an investment in the Company Continued
Appendix: Risks specific to an investment in the Company Continued Clinical trials and Development We are in the preclinical testing stages for our most advanced research programs. We have not initiated clinical development of any product candidate and expect that it will be many years, if ever, bef
Slide 22: Appendix: Risks specific to an investment in the Company Continued
Appendix: Risks specific to an investment in the Company Continued Drug Discovery and The Company is open to creating value through drug discovery and development alliances. This requires a flow of new contracts and/or Development alliance risk extensions of existing agreements to grow revenue. Whil
Slide 23: Appendix: Risks specific to an investment in the Company Continued
Appendix: Risks specific to an investment in the Company Continued Drug Discovery and The Company is open to creating value through drug discovery and development alliances. This requires a flow of new contracts and/or extensions Development alliance risk of existing agreements to grow revenue. Whil
Slide 24: Appendix: Risks specific to an investment in the Company Continued
Appendix: Risks specific to an investment in the Company Continued Product liability and uninsured Through its intended business, the Company is exposed to potential product liability risks which are inherent in the research and development, risks manufacturing, marketing and use of its products or
Slide 25: Appendix: Risks specific to an investment in the Company Continued
Appendix: Risks specific to an investment in the Company Continued Delay risk The Company is at an early stage in development and commercialisation of its technology and products and any material delays in this process may substantially increase the cost of development. Material delays could also re
Slide 26: Appendix: International Offer Restrictions
Appendix: International Offer Restrictions Offer Jurisdictions This document does not constitute an offer for shares in the Company in any jurisdiction which it would be unlawful. The Entitlement Offer is not being extended to any shareholder with a registered address outside Australia or New Zealan
Slide 27: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business of Phylogica Limited trading as PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarifica
PYC Therapeutics — Investor Presentation (October 2019) on 6ix